COMMUNIQUÉS West-GlobeNewswire

Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules
18/11/2025
THE WOODLANDS, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
18/11/2025
RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov. 18, 2025 (GLOBE [...]
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
18/11/2025
CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
18/11/2025
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz [...]
Inspire Medical Systems, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
18/11/2025
MINNEAPOLIS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
18/11/2025
JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s [...]
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
18/11/2025
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and [...]
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
18/11/2025
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on [...]
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
18/11/2025
CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
18/11/2025
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel [...]
Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit
18/11/2025
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled [...]
A natural breakthrough in protecting cereals and field crops
18/11/2025
Syngenta and Amoeba SA to develop and commercialize biocontrol solutions for EU and UK Chassieu, France Basel, Switzerland , Nov. 18, 2025 (GLOBE NEWSWIRE) -- Amoebas. These single-celled microorganisms are now at the [...]
Uma inovação natural na proteção de cereais e culturas agrícolas
18/11/2025
Syngenta e Amoéba SA vão desenvolver e comercializar soluções de biocontrolo na UE e no Reino Unido Basileia, Suíça Chassieu, França, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Uma inovação natural na proteção de cereais e [...]
HelixAI launches a new agentic operating system to bring the power of autonomous AI to life sciences
18/11/2025
PRESS RELEASE New operating system enables scientists to move from copilot to autopilot, unifying diverse in silico, wet lab research and scientists to accelerate innovation Partnerships with NVIDIA, AWS and Sapio [...]
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
18/11/2025
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, [...]
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
18/11/2025
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders Strategic initiative follows positive topline results from pivotal Phase 3 HERIZON- [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
18/11/2025
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapy These unprecedented results support its potential as a new [...]
Apollomics Announces Changes to its Board of Directors and Composition of Committees
18/11/2025
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following [...]
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
18/11/2025
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of [...]

Pages